US2023057793A1PendingUtilityA1

Arc-based capsids and uses thereof

70
Assignee: AERA THERAPEUTICS INCPriority: Sep 18, 2018Filed: Aug 8, 2022Published: Feb 23, 2023
Est. expirySep 18, 2038(~12.1 yrs left)· nominal 20-yr term from priority
Inventors:Colin MaloneIan PeikonZachary GilbertAndrey PisarevAdam FraitesJessica Crisp
C07K 14/161C07K 14/16C12N 15/111C07K 14/15A61K 39/0011C07K 14/46C12N 15/87C07K 2319/00A61P 35/00C12N 2310/3519A61K 9/127C12N 2310/20A61K 9/1658A61K 2039/80C12N 2310/12C12N 9/22C07K 16/00C07K 14/005A61K 39/39A61K 2039/55555C12N 2310/141C12N 2310/531A61K 9/5184A61K 2039/542C12N 2320/32C12N 15/85A61K 48/0008C12N 15/11C07K 14/435A61K 9/5169C12N 2740/10022A61K 38/00A61K 9/1075A61K 2039/51C12N 15/907
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein, in certain embodiments, are recombinant Arc and endogenous Gag polypeptides, and methods of using recombinant Arc and endogenous Gag polypeptides.

Claims

exact text as granted — not AI-modified
1 . A capsid comprising a recombinant endogenous Gag polypeptide and a heterologous cargo. 
     
     
         2 - 25 . (canceled)

Join the waitlist — get patent alerts

Track US2023057793A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.